Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan Gets Subpoena From Government Over Lap-Band System

05/07/2012 | 06:11pm US/Eastern
   By Anjali Athavaley 
   Of  
 

Allergan Inc. (AGN) received a subpoena this month from the Department of Health and Human Services requesting documents related to the company's Lap-Band System for obesity, according to a filing.

Lap-Band is approved to help obese patients lose weight. It is inserted surgically through a small incision and placed at the top of the stomach. The inflatable band can be tightened or loosened to reduce or enlarge stomach capacity.

An Allergan spokeswoman declined to comment further.

Earlier this month, Allergan said its first-quarter earnings rose 45% on double-digit sales growth in its specialty-pharmaceuticals business. But sales in Allergan's obesity intervention category slipped 15.5% as high unemployment, lofty co-payments and rigid requirements from insurers pressured sales.

Last December, the U.S. Food and Drug Administration warned nine groups, mostly surgical centers in California, that if they continue misleading advertising for Lap-Band, they could face monetary penalties and have inventory seized. The FDA made no allegations against Allergan at the time.

Allergan shares were up fractionally to $93.79 in after-hours trading Monday. The stock is up nearly 7% so far this year.

-By Anjali Athavaley, Dow Jones Newswires; 212-416-4912; anjali.athavaley@dowjones.com

React to this article
Latest news on ALLERGAN, INC.
09:09a ALLERGAN : Healthpointe's Cosmetic Laser Institute Now Providing Juvéderm Voluma..
08:56a ALLERGAN : Entry into a Material Definitive Agreement, Other Events, Financial S..
06:15a Hikma to buy Boehringer's U.S. generic drug business for $2.65 billion
04:23a TEVA PHARMACEUTICAL : to buy Allergan generic business for $40.5 billion, drops ..
03:25a Hikma to buy Boehringer's U.S. generics unit for $2.65 billion
01:11a ALLERGAN : Teva's Allergan bid succeeds as Mylan deal fails
07/27 Mylan independence from Teva's embrace comes with a price
07/27 ALLERGAN : Business Highlights
07/27 Wall Street drops as China stock slump stokes growth fears
07/27 ALLERGAN : Other Events, Financial Statements and Exhibits (form 8-K)
Advertisement
Income Statement Evolution
More Financials